Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents

Table 2 DAA regimens, results and observed side effects (n = 305)

Characteristic	Total
Characteristic	n	%
Treatment (2 missing data)
SOF, LDV	152	50
SOF, DCV	37	12
SOF, LDV, RBV	25	8
DSV, OBV, PTV, RTV	19	6
DSV, OBV, PTV, RTV, RBV	15	5
SOF, SMV	14	4
GCP, PBV	12	4
SOF, RBV	11	3
SOF, VEL	7	3
EBV, GZP	5	2
SOF, RBV, PEG-IFN	3	2
SOF, DCV, RBV	2	< 2
EBV, GZP, RBV	1	< 1
Treatment results
Directly after therapy (16 missing data)
ETR	285	99
Remission/viral load unchanged	4	1
12 weeks after treatment (no missing data)
SVR12	300	98
Remission/viral load unchanged	1	< 1
Relapse	5	1
24 weeks after treatment (53 missing data)
SVR24	246	98
Remission/viral load unchanged	5	2
Relapse	0	0
Side effects (1 missing data)
None	212	70
Headaches, nausea, sleep disorder	60	20
Skin reactions	11	4
Joint and muscle pain	7	2
Depression, anxiety	4	1
Anaemia	3	1
Gastrointestinal disorders	3	1
Other^a	4	1

^a Expression of advanced infection (hepatorenal syndrome n = 2, bleeding of the oesophageal varices n = 1, kidney failure and pancreatitis n = 1), DAA Direct-acting antiviral agents, DCV Daclatasvir, DSV Dasabuvir, EBV Elbasvir, GCP Glecaprevir, GZP Grazoprevir, LDV Ledipasvir, SOF Sofosbuvir, OBV Ombitasvir, PTV Paritaprevir, PBV Pibrentasvir, RBV Ribavirin, RTV Ritonavir, VEL Velpatasvir, SMV Simeprevir, PEG-IFN pegylated interferon, ETR End of treatment response, SVR12 Sustained virological response 12 weeks after end of treatment, SVR24 Sustained virological response 24 weeks after end of treatment

ISSN: 1745-6673